Rodman & Renshaw reiterated its BioDelivery Sciences BDSI Market Outperform rating and $5.50 price target in a research report published today.
In the report, Rodman & Renshaw states, "As we've noted since in our August 2010 initiation, we find more value in BDSI's pipeline than Onsolis has or could ever produce."
Shares of BioDelievery Sciences were trading at $3.08 at the time of posting, down 4.80% from Thursday's market close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in